Carbohydrate-based vaccine adjuvants - discovery and development (Q38587300)

4 September 2017

Carbohydrate-based vaccine adjuvants - discovery and development (English)

1 reference

4 September 2017

Jing Hu

1

1 reference

4 September 2017

Liying Qiu

2

1 reference

4 September 2017

Xiaoli Wang

3

1 reference

4 September 2017

Xiaopeng Zou

4

1 reference

4 September 2017

Mengji Lu

5

1 reference

4 September 2017

Jian Yin

6

1 reference

4 September 2017

language of work or name

English

0 references

publication date

15 September 2015

1 reference

Expert Opinion on Drug Discovery

4 September 2017

1 reference

4 September 2017

10

1 reference

4 September 2017

10

1 reference

4 September 2017

1133-1144

1 reference

New vaccine technology--what do you need to know?

4 September 2017

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1067198

Vaccine adjuvant: it makes the difference

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1067198

Vaccine adjuvants: current state and future trends

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1067198

Key roles of adjuvants in modern vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1067198

Poly(lactide-co-glycolide) microparticles for the development of single-dose controlled-release vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1067198

Macrophagic myofasciitis: an emerging entity. Groupe d'Etudes et Recherche sur les Maladies Musculaires Acquises et Dysimmunitaires (GERMMAD) de l'Association Française contre les Myopathies (AFM).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1067198

Autoimmune/inflammatory syndrome induced by adjuvants (Shoenfeld's syndrome): clinical and immunological spectrum

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1067198

Carbohydrate-based immune adjuvants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1067198

Adjuvants: current status, clinical perspectives and future prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1067198

Lipopolysaccharide endotoxins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1067198

Crystal structure of the TLR4-MD-2 complex with bound endotoxin antagonist Eritoran

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1067198

Crystal structures of human MD-2 and its complex with antiendotoxic lipid IVa

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1067198

The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1067198

Monophosphoryl lipid A (MPL) as an adjuvant for anti-cancer vaccines: clinical results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1067198

Immunobiological activities of nontoxic lipid A: enhancement of nonspecific resistance in combination with trehalose dimycolate against viral infection and adjuvant effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1067198

Safety evaluation of monophosphoryl lipid A (MPL): an immunostimulatory adjuvant.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1067198

Enhancement of antigen-specific immunity via the TLR4 ligands MPL adjuvant and Ribi.529.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1067198

Selective activation of the p38 MAPK pathway by synthetic monophosphoryl lipid A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1067198

GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1067198

Recent clinical experience with vaccines using MPL- and QS-21-containing adjuvant systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1067198

Nonclinical reproductive and developmental safety evaluation of the MAGE-A3 Cancer Immunotherapeutic, a therapeutic vaccine for cancer treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1067198

Local tolerance and systemic toxicity of single and repeated intramuscular administrations of two different formulations of the RTS,S malaria candidate vaccine in rabbits.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1067198

Enhancement of adaptive immunity by the human vaccine adjuvant AS01 depends on activated dendritic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1067198

Vaccine Adjuvant Systems containing monophosphoryl lipid A and QS-21 induce strong humoral and cellular immune responses against hepatitis B surface antigen which persist for at least 4 years after vaccination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1067198

Evaluation of the intramuscular administration of Cervarix™ vaccine on fertility, pre- and post-natal development in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1067198

AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1067198

Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1067198

Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1067198

Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1067198

New hepatitis B vaccine formulated with an improved adjuvant system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1067198

Immunotherapy of an ascitic rat hepatoma with cord factor (trehalose-6, 6'-dimycolate) and synthetic analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1067198

Natural and synthetic trehalose diesters as immunomodulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1067198

Activation of protein kinase C by mycobacterial cord factor, trehalose 6-monomycolate, resulting in tumor necrosis factor-alpha release in mouse lung tissues.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1067198

Effects of mycobacterial fractions and muramyl dipeptide on the resistance of mice to aerogenic influenza virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1067198

Adjuvanticity of a synthetic cord factor analogue for subunit Mycobacterium tuberculosis vaccination requires FcRgamma-Syk-Card9-dependent innate immune activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1067198

Cutting edge: Mincle is essential for recognition and adjuvanticity of the mycobacterial cord factor and its synthetic analog trehalose-dibehenate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1067198

The mycobacterial cord factor adjuvant analogue trehalose-6,6'-dibehenate (TDB) activates the Nlrp3 inflammasome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1067198

Characterization of cationic liposomes based on dimethyldioctadecylammonium and synthetic cord factor from M. tuberculosis (trehalose 6,6'-dibehenate)-a novel adjuvant inducing both strong CMI and antibody responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1067198

Control of chronic mycobacterium tuberculosis infection by CD4 KLRG1- IL-2-secreting central memory cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1067198

Vaccine-induced th17 cells are maintained long-term postvaccination as a distinct and phenotypically stable memory subset

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1067198

A multistage tuberculosis vaccine that confers efficient protection before and after exposure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1067198

New pathways of protective and pathological host defense to mycobacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1067198

A novel liposomal adjuvant system, CAF01, promotes long-lived Mycobacterium tuberculosis-specific T-cell responses in human

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1067198

Saponin-adjuvanted particulate vaccines for clinical use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1067198

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1067198

Formulation of the purified fusion protein of respiratory syncytial virus with the saponin QS-21 induces protective immune responses in Balb/c mice that are similar to those generated by experimental infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1067198

A strong CD8+ T cell response is elicited using the synthetic polypeptide from the C-terminus of the circumsporozoite protein of Plasmodium berghei together with the adjuvant QS-21: quantitative and phenotypic comparison with the vaccine model of ir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1067198

Induction of homologous virus neutralizing antibodies in guinea-pigs immunized with two human immunodeficiency virus type 1 glycoprotein gp120-iscom preparations. A comparison with other adjuvant systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1067198

QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immmunization in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1067198

Preclinical evaluation of a synthetic Plasmodium falciparum MAP malaria vaccine in Aotus monkeys and mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1067198

Safety, tolerability and immunogenicity of new formulations of the Plasmodium falciparum malaria peptide vaccine SPf66 combined with the immunological adjuvant QS-21.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1067198

Humoral and cell-mediated immune responses of humans to inactivated influenza vaccine with or without QS21 adjuvant

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1067198

Effective immunotherapy against canine visceral leishmaniasis with the FML-vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1067198

Pulcherrimasaponin, from the leaves of Calliandra pulcherrima, as adjuvant for immunization in the murine model of visceral leishmaniasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1067198

Phase 1 trial of immunological adjuvant QS-21 with a GM2 ganglioside-keyhole limpet haemocyanin conjugate vaccine in patients with malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1067198

Immunization of metastatic breast cancer patients with a fully synthetic globo H conjugate: a phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1067198

Immunization of high-risk breast cancer patients with clustered sTn-KLH conjugate plus the immunologic adjuvant QS-21.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1067198

Carbohydrate-based vaccines with a glycolipid adjuvant for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1067198

Fully synthetic carbohydrate-based vaccines in biochemically relapsed prostate cancer: clinical trial results with alpha-N-acetylgalactosamine-O-serine/threonine conjugate vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1067198

Vaccination of patients with small-cell lung cancer with synthetic fucosyl GM-1 conjugated to keyhole limpet hemocyanin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1067198

Vaccination of small cell lung cancer patients with polysialic acid or N-propionylated polysialic acid conjugated to keyhole limpet hemocyanin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1067198

Pilot study of a heptavalent vaccine-keyhole limpet hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1067198

ISCOMATRIX adjuvant for prophylactic and therapeutic vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1067198

Natural and synthetic saponin adjuvant QS-21 for vaccines against cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1067198

Achieving directed immunostimulating complexes incorporation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1067198

Synthetic studies of complex immunostimulants from Quillaja saponaria: synthesis of the potent clinical immunoadjuvant QS-21Aapi.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1067198

Synthesis of the potent immunostimulatory adjuvant QS-21A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1067198

Synthesis of QS-21-xylose: establishment of the immunopotentiating activity of synthetic QS-21 adjuvant with a melanoma vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1067198

Design and synthesis of potent Quillaja saponin vaccine adjuvants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1067198

Fractionation, structural studies, and immunological characterization of the semi-synthetic Quillaja saponins derivative GPI-0100.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1067198

Effect of immunization with herpes simplex virus type-1 (HSV-1) glycoprotein D (gD) plus the immune enhancer GPI-0100 on infection with HSV-1 or HSV-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1067198

Effect of an immune enhancer, GPI-0100, on vaccination with live attenuated herpes simplex virus (HSV) type 2 or glycoprotein D on genital HSV-2 infections of guinea pigs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1067198

Advances in saponin-based adjuvants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1067198

Synthesis and preclinical evaluation of QS-21 variants leading to simplified vaccine adjuvants and mechanistic probes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1067198

Development of a minimal saponin vaccine adjuvant based on QS-21

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1067198

The polysaccharide inulin is characterized by an extensive series of periodic isoforms with varying biological actions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1067198

Inulin glasses for the stabilization of therapeutic proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1067198

Development of a dried influenza whole inactivated virus vaccine for pulmonary immunization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1067198

Inulin sugar glasses preserve the structural integrity and biological activity of influenza virosomes during freeze-drying and storage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1067198

Novel human polysaccharide adjuvants with dual Th1 and Th2 potentiating activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1067198

Inulin-derived adjuvants efficiently promote both Th1 and Th2 immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1067198

Potentiation of photodynamic therapy of cancer by complement: the effect of gamma-inulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1067198

Delta inulin: a novel, immunologically active, stable packing structure comprising β-D-[2 -> 1] poly(fructo-furanosyl) α-D-glucose polymers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1067198

An inactivated Vero cell-grown Japanese encephalitis vaccine formulated with Advax, a novel inulin-based adjuvant, induces protective neutralizing antibody against homologous and heterologous flaviviruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1067198

Induction of mucosal and systemic antibody and T-cell responses following prime-boost immunization with novel adjuvanted human immunodeficiency virus-1-vaccine formulations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1067198

Advax™, a polysaccharide adjuvant derived from delta inulin, provides improved influenza vaccine protection through broad-based enhancement of adaptive immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1067198

Randomized clinical trial of immunogenicity and safety of a recombinant H1N1/2009 pandemic influenza vaccine containing Advax™ polysaccharide adjuvant

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1067198

An inactivated cell culture Japanese encephalitis vaccine (JE-ADVAX) formulated with delta inulin adjuvant provides robust heterologous protection against West Nile encephalitis via cross-protective memory B cells and neutralizing antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1067198

A novel hepatitis B vaccine containing Advax™, a polysaccharide adjuvant derived from delta inulin, induces robust humoral and cellular immunity with minimal reactogenicity in preclinical testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1067198

A gold glyco-nanoparticle carrying a Listeriolysin O peptide and formulated with Advax™ delta inulin adjuvant induces robust T-cell protection against listeria infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1067198

Immunogenicity and safety of Advax™, a novel polysaccharide adjuvant based on delta inulin, when formulated with hepatitis B surface antigen: a randomized controlled Phase 1 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1067198

Advax-adjuvanted recombinant protective antigen provides protection against inhalational anthrax that is further enhanced by addition of murabutide adjuvant

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1067198

Development of soluble inulin microparticles as a potent and safe vaccine adjuvant and delivery system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1067198

Acylated and deacylated saponins of Quillaja saponaria mixture as adjuvants for the FML-vaccine against visceral leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1067198

Peptide vaccines derived from a malarial surface antigen: effects of dose and adjuvants on immunogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1067198

10.1517/17460441.2015.1067198

21 January 2018

Identifiers

DOI

1 reference

4 September 2017

1 reference